To appease a patient lobby, did the FDA approve a $300,000 drug that doesn't work?
A couple of weeks ago, the big insurance company Anthem decided that it wouldn’t pay for Exondys 51, a drug that already had been approved by the Food and Drug Administration to treat Duchenne muscular dystrophy.
Anthem’s decision was controversial, because two other insurers had said they’d cover the treatment for their patients. But it was less controversial than it could have been for two reasons: The drug costs $300,000 a year, and the evidence that it works is almost laughably thin. To put it another way, Anthem’s decision undoubtedly infuriated advocates for DMD patients, but it may well have been the right call.
Read the full article here.